# A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

> **NCT06181591** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Mirabegron 50 MG
- **DRUG:** Oxybutynin Chloride 5 MG

## Key facts

- **NCT ID:** NCT06181591
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-04-15
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06181591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06181591, "A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06181591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*